Status:
COMPLETED
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
Lead Sponsor:
GlaxoSmithKline
Collaborating Sponsors:
The PATH Malaria Vaccine Initiative (MVI)
Conditions:
Malaria
Malaria Vaccines
Eligibility:
All Genders
6-9 years
Phase:
PHASE4
Brief Summary
This epidemiology study was conducted in parallel with the EPI-MAL-002 (NCT02374450) and EPI-MAL-003 (NCT03855995) studies, enrolling participants from the same health and demographic surveillance sys...
Detailed Description
This study involved 10 annual cross-sectional surveys conducted during malaria peak transmission seasons. The surveys provided point estimates of parasite prevalence and subsequently enabled a longitu...
Eligibility Criteria
Inclusion
- Participants whose parent(s)/Legally Acceptable Representative(s) \[LAR(s)\], in the opinion of the investigator, could and would comply with the requirements of the protocol.
- A male or female aged 6 months to under 10 years at the time of the survey.
- Signed informed consent or thumb-printed and witnessed informed consent was obtained from the parent(s)/LAR(s) of the child.
Exclusion
- Child was in care.
- Had current active participation in any trial involving administration of an investigational malaria vaccine or malaria drug.
Key Trial Info
Start Date :
October 22 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 6 2024
Estimated Enrollment :
54115 Patients enrolled
Trial Details
Trial ID
NCT02251704
Start Date
October 22 2014
End Date
July 6 2024
Last Update
July 24 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Nouna, Burkina Faso
2
GSK Investigational Site
Ouagadougou, Burkina Faso, 2208
3
GSK Investigational Site
Kintampo, Ghana
4
GSK Investigational Site
Navrongo, Ghana